New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Denali Therapeutics Inc.
DNLI
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

4B

Biotechnology

Next Earning date - 05 Nov 2024

4B

Biotechnology

Next Earning date - 05 Nov 2024

27.25USD
Shape-0.53 ( -1.91%)
Market Open
favorite-chart

Relative Strenght

17
favorite-chart

Volume Buzz

62%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

15%

Quote Panel

Shape
Updated October 29, 2024
1W 4.31 % 1M -6.61 % 3M 12.37 % 1Y 47.85 %

Key Metrics

Shape
  • Market Cap

    3.90B


  • Shares Outstanding

    143.17M


  • Share in Float

    119.11M


  • Dividende

    0


  • Earning Date

    05 Nov 2024


  • Price Target

    27.25


  • Average Volume

    855310


  • Beta

    1.378


  • Range

    14.56-32.132


  • Industry

    Biotechnology


  • Website

    https://www.denalitherapeutics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

Nanx

P/S Ratio

3.38x

P/B Ratio

0.0

Debt/Equity

138.1%

Net Margin

$-2.9

EPS

How DNLI compares to sector?

P/E Ratio

Relative Strength

Shape

DNLI

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$65M

ShapeNaN%

2025-Revenue

$2.62

Shape-344%

2025-EPS

$44M

Shape62%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Cantor Fitzgerald

downgrade

Previous: Not converted

2024-10-07

Now: Neutral

B. Riley Securities

initialise

Previous: Not converted

2023-09-06

Now: Buy

Cowen & Co.

initialise

Previous: Not converted

2022-12-05

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.84
vs -0.69

Q4.22

arrow
arrow

N/A

-0.75
vs -0.62

Q1.23

arrow
arrow

N/A

-0.80
vs -0.53

Q2.23

arrow
arrow

+371%

1.3
vs -0.48

Q3.23

arrow
arrow

N/A

-0.72
vs -0.84

Q4.23

arrow
arrow

N/A

-0.86
vs -0.75

Q1.24

arrow
arrow

N/A

-0.68
vs -0.80

Q2.24

arrow
arrow

N/A

-0.59
vs 1.3

Q3.24

arrow
arrow

N/A

-0.60
vs -0.72

Q4.24

arrow
arrow

N/A

-0.61
vs -0.86

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-33%

3.6M  vs 5.3M

Q4.22

arrow
arrow

-18%

10.3M  vs 12.5M

Q1.23

arrow
arrow

-17%

35.1M  vs 42.1M

Q2.23

arrow
arrow

+460%

294.1M  vs 52.5M

Q3.23

arrow
arrow

-64%

1.3M  vs 3.6M

Q4.23

arrow
arrow

-3066%

-305043000.00  vs 10.3M

Q1.24

arrow
arrow

-100%

NA  vs 35.1M

Q2.24

arrow
arrow

-100%

NA  vs 294.1M

Q3.24

arrow
arrow

+397%

6.3M  vs 1.3M

Q4.24

arrow
arrow

+105%

15.1M  vs -305043000

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-13%

-0.13
vs -0.07

Q4.22

arrow
arrow

-9%

-0.09
vs -0.13

Q1.23

arrow
arrow

-11%

-0.11
vs -0.09

Q2.23

arrow
arrow

+15%

0.15
vs -0.11

Q3.23

arrow
arrow

-9%

-0.09
vs 0.15

Q4.23

arrow
arrow

-12%

-0.12
vs -0.09

Q1.24

arrow
arrow

-7%

-0.07
vs -0.12

Q2.24

arrow
arrow

-7%

-0.07
vs -0.07

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

198

198
vs 181

9%

Q4.22

arrow
arrow

199

199
vs 198

1%

Q1.23

arrow
arrow

202

202
vs 199

2%

Q2.23

arrow
arrow

201

201
vs 202

0%

Q3.23

arrow
arrow

197

197
vs 201

-2%

Q4.23

arrow
arrow

218

218
vs 197

11%

Q1.24

arrow
arrow

212

212
vs 218

-3%

Q2.24

arrow
arrow

204

204
vs 212

-4%

Earnings Growth

Latest News